High Throughput Screening Market
Number of pages: 100 | Report Format: PDF | Published date: November 09, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 16.7 billion |
|
Revenue forecast in 2030 |
US$ 41.01 billion |
|
Growth Rate |
CAGR of 10.5% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
technology, application, end-user, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth+ Reports, the global high throughput screening market was pegged at US$ 16.7 billion in 2021. The market is expected to witness a CAGR of 10.5% from 2022 to 2030.
Market Fundamentals
High-throughput screening (HTS) is a drug discovery approach that enables automated testing of numerous chemical and biological substances for a particular biological target, for instance, by binding tests. In the pharmaceutical sector, high-throughput screening techniques are widely utilized to quickly assess the biological or biochemical activity of many compounds, typically drugs. These techniques make use of robotics and automation. They speed up target analysis since vast compound libraries can be swiftly and affordably screened. HTS is a helpful approach for evaluating pharmacological targets, pharmacologically profiled agonists, and antagonists for receptors (such as GPCRs) and enzymes.
[938754]
Market Dynamics
The increased use of high throughput screening in drug discovery and development as it reduces the time required is the main driving factor of the global high throughput screening market. Moreover, the rise in the total spending on research and development by biotech and pharma companies is also playing a pivotal role in the growth of the global market. The growing application of high throughput screening in life science and the continuous innovation in drug development for life-threatening diseases is also increasing the demand for high throughput screening. Furthermore, the rising government initiatives and investments in drug development are also fueling the growth of the global market. The increased adoption of advanced technologies in high throughput screening, such as AI and machine learning, is boosting the market growth. The development of novel treatments for many life-threatening disorders and the use of open innovation techniques in the pharmaceutical and biotechnology industries are assisting in the market's growth. However, the lack of skilled professionals and welled software need-developed software is needed for data accumulation, thus restricting the global high throughput screening market. Moreover, the cost of HTS in developing countries is high, which is also hampering the growth of the global market.
Market Ecosystem
The global high throughput screening market has been analyzed from four perspectives: technology, application, end-user, and region.
High Throughput Screening Market by technology
[2312313]
Based on technology, the global high throughput screening market is segmented into cell-based assays, 3D - cell culture, ultra-high throughput screening, lab-on-a-chip technology (LOC), label-free technology. The cell-based assays segment dominates the global high throughput screening market with the highest market share in 2021. The cell-based assays segment is further sub-segmented into fluorometric imaging plate reader assays and reporter-based assays. The large share of the cell-based assays segment can be attributed to the increased use of fluorometric imaging plate reader assays. It is the most used method of cell-based assays as it provides visible results and the test can be performed with a small sample. Moreover, the fluorometric imaging plate reader assays provide real time data, sensitivity, data fidelity, and kinetic information of the sample, thus increasing the demand for fluorometric imaging plate reader assays.
High Throughput Screening Market by Application
Based on application, the global high throughput screening market is classified into drug discovery programs, biochemical screening, chemical biology programs, and cell & organ-based screening. The drug discovery segment holds the largest market share of the global high throughput screening market in 2021. The rise in the investment by the top player and government organizations in the R&D of new drugs for the treatment of life-threatening diseases is the key factor propelling the segment growth. Moreover, many research institutes are working in the field of drug development, thus boosting the segment growth. The use of HTS reduces the overall cost of drug discovery, hence a considerable number of pharma and biotech companies are investing in drug discovery, fueling the segment growth.
High Throughput Screening Market by End-user
Based on end-user, the global high throughput screening market is divided into pharmaceutical and biotechnology companies, research institutes and academia, contract research organizations (CROs) and others. The contract research organizations lead the global high throughput screening market with the largest market share in 2021. The rising outsourcing tendencies in the clinical trials sector are playing a pivotal role in the growth of the global contract research organization. Moreover, the rise in the number of clinical trials due the increase in the development of novel drugs is also increasing the demand for CRO. The rising cost of in-house drugs development is leading the pharma companies to opt for outsourcing, thus increasing the demand for CROs.
High Throughput Screening Market by Region
Based on region, the global high throughput screening market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global high throughput screening market in 2021, followed by Europe. The large share of North America can be attributed to the rise in R&D in the region with the rising initiative by the government organization for drug development and discovery. Moreover, the presence of the major players and research institutes in the region is also boosting the regional growth.
Competitive Landscape
The prominent players operating in the high throughput screening market are:
Strategic Developments
The global high throughput screening market is estimated to reach US$ 41.01 billion in 2030.
The rise in the investment by the major player in R&D related to drug discovery is boosting market growth. Moreover, the rise in government initiatives and investment in drug development is also increasing the demand for HTS. The adoption of advanced technology in HTS is also propelling the market growth.
The key competitors in the global high throughput screening market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, PerkinElmer Inc., Tecan Group Ltd, Bio-Rad Laboratories, Merck KGaA, Hamilton Company, Axxam S.p.A., Aurora Biomed, Corning Incorporated, Promega Corporation, Lonza, Solvias AG, Charles River Laboratories, and REPROCELL Inc. among others.
Geographically, North America has the largest market share followed by Europe; and Asia Pacific is the fastest growing regional market for high throughput screening.
The lack of skilled professional and software which are required for the analysis of data. The cost of HTS is the developing countries is high this are some of the restricting factors of the global market.
*Insights on financial performance are subject to the availability of information in the public domain